Core Viewpoint - The company, Lanke Technology, is actively engaging in share repurchase and plans to issue H-shares for further capital raising and market expansion [1][2][3] Group 1: Stock Performance - As of June 27, 2025, Lanke Technology's stock closed at 80.15 yuan, down 1.74% from the previous week [1] - The stock reached a weekly high of 81.5 yuan and a low of 77.45 yuan [1] - The company's total market capitalization is 91.755 billion yuan, ranking 7th in the semiconductor sector and 151st among all A-shares [1] Group 2: Share Repurchase - The company announced its first share repurchase plan for 2025, with a total repurchase amount of 2 billion to 4 billion yuan [2] - As of June 23, 2025, the company has repurchased 450,000 shares, accounting for 0.04% of the total share capital, with a total expenditure of approximately 35.1176 million yuan [1][3] - The repurchase price range was between 77.79 yuan and 78.29 yuan per share [1] Group 3: Upcoming Events - Lanke Technology will hold its first extraordinary general meeting on July 7, 2025, to discuss several proposals, including the issuance of H-shares and amendments to the company's articles of association [2][3] - The company plans to issue H-shares on the Hong Kong Stock Exchange, with a maximum issuance not exceeding 9% of the total share capital post-issuance [2] - The funds raised from the H-share issuance will primarily be used for cutting-edge technology research in interconnected chips and global market expansion [2]

Core Viewpoint - The company has successfully completed its share repurchase plan, which was aimed at implementing an equity incentive program, with a total repurchase amount between RMB 30 million and RMB 60 million [1][3]. Summary by Sections Implementation of Share Repurchase - The company initiated its share repurchase on July 1, 2024, through a centralized bidding method, and has committed to disclosing the progress of the repurchase on a monthly basis [2]. Results of Share Repurchase - As of June 26, 2025, the company repurchased a total of 13,964,923 shares, representing 1.35% of the total share capital of 1,032,935,798 shares. The highest transaction price was RMB 3.15 per share, while the lowest was RMB 0.99 per share, with a total transaction amount of RMB 30,020,188 (excluding transaction fees) and an average repurchase price of RMB 2.15 per share [3]. Compliance and Impact - The share repurchase complies with relevant laws and regulations and will not significantly impact the company's financial, operational, or debt obligations. It also does not affect the control structure of the company [4]. Shareholder Transactions - During the repurchase period, there were no stock trading activities by the company's directors, supervisors, senior management, controlling shareholders, or actual controllers [6]. Compliance with Regulations - The company adhered to all regulatory requirements regarding the timing, quantity, and pricing of the share repurchase, ensuring no violations occurred during the process [7][8]. Changes in Share Capital - The repurchased shares will be used for an equity incentive plan, which has not yet been implemented. If the shares are not utilized within 36 months, the unutilized portion will be canceled, leading to a reduction in total share capital [9][10].

Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to adopt an equity incentive program for its subsidiary, WuXi Biologics, which includes a stock option plan and a restricted stock unit plan aimed at attracting and retaining skilled personnel [2][7][30]. Group 1: Overview of the Equity Incentive Plan - The equity incentive plan consists of two independent programs: (1) a stock option plan and (2) a restricted stock unit plan [2][7]. - The total number of stock options and restricted stock units to be granted under these plans will not exceed 8% of WuXi Biologics' total shares (excluding treasury shares) as of the adoption date [3][8]. - As of the announcement date, WuXi Biologics has a total of 543,494,853 shares, with the group holding 63.43% of the shares [3][28]. Group 2: Initial Grant Details - The initial grant will involve issuing a total of 6.985 million stock options and 6.985 million restricted stock units to 279 qualified individuals, with an exercise price of HKD 50.25 per share for stock options and a vesting price of RMB 1 per restricted stock unit [3][24][25]. - The initial grant is subject to approval by WuXi Biologics' shareholders and will not constitute a related party transaction [4][10][27]. Group 3: Purpose and Conditions of the Plan - The purpose of the equity incentive plan is to attract, motivate, and retain skilled personnel, recognizing their contributions and encouraging them to enhance the value of WuXi Biologics [11][30]. - The plan's effectiveness requires approval from WuXi Biologics' shareholders and compliance with the Hong Kong Stock Exchange's listing rules [13][32]. Group 4: Financial Overview of WuXi Biologics - WuXi Biologics, established in February 2010 and listed on the Hong Kong Stock Exchange in September 2019, focuses on the research, production, and sales of monoclonal antibody drugs [28]. - As of December 31, 2024, WuXi Biologics reported total assets of RMB 1,059.75 million, total liabilities of RMB 758.39 million, and a net profit of RMB 82.05 million [29].

Group 1 - The company held the 29th meeting of the 11th Supervisory Board on June 27, 2025, via electronic communication, with all three supervisors participating, complying with relevant laws and regulations [1] - The Supervisory Board approved the draft of the 2025 equity incentive plan, which aligns with the Company Law, Securities Law, and other regulatory requirements, and is expected to benefit the company's sustainable development without harming the interests of shareholders [1][2] - The Supervisory Board also approved the implementation assessment management measures for the 2025 equity incentive plan, which are designed to ensure smooth execution and improve the company's governance structure and value distribution system [2] Group 2 - The Supervisory Board verified the list of incentive recipients for the 2025 equity incentive plan, confirming that all candidates meet the qualifications set forth by relevant laws and regulations [3] - The incentive recipients do not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares, ensuring compliance with legal stipulations [3] - The company will publicly disclose the names and positions of the incentive recipients on its website for a minimum of 10 days, allowing for feedback before final approval at the shareholders' meeting [3]

Core Viewpoint - The company, Jiangsu Aidi Pharmaceutical Co., Ltd., has proposed a stock option incentive plan aimed at attracting and retaining talent, aligning the interests of shareholders, the company, and its core team for long-term development [6][7]. Summary by Sections Incentive Plan Overview - The incentive plan involves granting 11.375 million stock options, representing approximately 2.703% of the company's total share capital of 420,782,808 shares [2][11]. - The initial grant consists of 9.1 million options, accounting for 2.163% of the total share capital, while 2.275 million options are reserved [2][11]. Stock Option Details - The exercise price for the stock options is set at 13.01 yuan per share [4][17]. - The plan allows for adjustments to the number of options or exercise price in case of capital increases, stock dividends, or other corporate actions [3][27]. Eligible Participants - A total of 45 individuals will receive the initial stock options, representing 6.392% of the company's projected employee count of 704 by the end of 2024 [3][9]. - The plan excludes independent directors and supervisors from participation [4][10]. Plan Duration and Conditions - The incentive plan is valid for a maximum of 48 months from the date of the first grant [6][12]. - The plan includes specific performance targets for both company-level and individual-level assessments to determine the eligibility for exercising options [20][18]. Management and Approval Process - The shareholders' meeting is the highest authority for approving the plan, while the board of directors is responsible for its execution [7][21]. - The plan must be publicly disclosed and approved by shareholders, requiring a two-thirds majority vote [22][23]. Performance Assessment - The performance assessment for the company includes revenue and net profit targets for the years 2025 and 2026, with specific thresholds for option exercise eligibility [20][18]. - Individual performance will also be evaluated, impacting the number of options that can be exercised [19][20]. Adjustments and Compliance - The plan includes provisions for adjusting stock options and exercise prices in response to corporate actions such as stock splits or dividends [27][26]. - The company commits to not providing financial assistance for exercising options, ensuring compliance with relevant laws and regulations [10][4].

Core Viewpoint - The report discusses the achievement of the conditions for the second unlock period of the first grant of restricted stock and the first unlock period of the reserved grant under the stock incentive plan of Steel Research Nake Testing Technology Co., Ltd. [3][6][29] Group 1: Stock Incentive Plan Overview - The stock incentive plan involves granting restricted stocks to employees, with specific unlock conditions and periods defined [3][4] - The first grant of restricted stocks was completed on July 1, 2022, with a total of 6,810,000 shares granted [9] - The second unlock period for the first grant is set to occur between 36 to 48 months after the initial grant [15][16] Group 2: Unlock Conditions - For the second unlock period, 33% of the granted shares can be unlocked if certain conditions are met, including the absence of adverse audit opinions and the fulfillment of performance targets [15][18] - The performance target for the year 2023 includes achieving a net profit of RMB 138,649,481.39, representing a compound annual growth rate of 21.54% from 2020 [19][25] Group 3: Reserved Grant Details - The reserved grant's first unlock period is defined as 24 to 36 months after the completion of the grant registration, with a similar unlock ratio of 33% [23][25] - The performance targets for the reserved grant are aligned with the overall company performance metrics, ensuring that the conditions for unlocking are consistent with the company's financial health [25][29] Group 4: Independent Financial Advisor's Opinion - The independent financial advisor confirms that the conditions for both the second unlock period of the first grant and the first unlock period of the reserved grant have been met, complying with relevant laws and regulations [20][29] - The advisor emphasizes the need for the company to disclose information and complete necessary procedures with the Shenzhen Stock Exchange following the unlock [20][29]

四川省成都市东御街 18 号百扬大厦 1 栋 11 楼邮编：610000 网址/WEBSITE：www.kangdacdlawyers.com 北京康达（成都）律师事务所 关 于 四川路桥建设集团股份有限公司 解除限售条件成就以及回购注销部分限制性股票的 法律意见书 康达（成都）法意字2025第 0372 号 二〇二五年六月 北京 BEIJING 上海 SHANGHAI 广州 GUANGZHOU 深圳 SHENZHEN 海口 HAIKOU 西安 XI'AN 天津 TIANJIN 杭州 HANGZHOU 南京 NANJING 沈阳 SHENYANG 成都 CHENGDU 菏泽 HEZE 苏州 SUZHOU 武汉 WUHAN 香港 HONGKONG 呼和浩特 HUHEHAOTE 1 厦门 XIAMEN 长沙 CHANGSHA 重庆 CHONGQING 郑州 ZHENGZHOU 合肥 HEFEI 宁波 NINGBO 济南 JINAN 昆明 KUNMING 南昌 NANCHANG 法律意见书 目 录 | 法律意见书 | | | --- | --- | | 释 | 义 | | 在本《法律意见书》中，除非文义另有所指，下 ...

序号 姓名 职务 科沃斯机器人股份有限公司董事会 科沃斯机器人股份有限公司 （预留授予日） 一、股票期权激励计划预留部分的分配情况 获授的股票期 占预留授予股 占预留授予 序号 姓名 职务 权数量 票期权总数的 公告日股本 （万份） 比例 总额的比例 中层管理人员、核心技术（业务）人 员以及公司其他骨干员工（506 人） 总计 339.76 100.00% 0.59% 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票 累计未超过本激励计划草案公告时公司股本总额的 1%。公司全部在有效期内的股权激励计 划所涉及的标的股票总数累计未超过本激励计划草案公告时公司股本总额的 10%。 司 5%以上股份的股东或实际控制人及其配偶、父母、子女。 二、其他激励对象名单 序号 姓名 职务 三、限制性股票激励计划预留部分的分配情况 获授的限制性 占预留授予限 占预留授予 序号 姓名 职务 股票数量 制性股票总数 公告日股本 （万股） 的比例 总额的比例 中层管理人员、核心技术（业务）人 员以及公司其他骨干员工（483 人） 总计 155.81 100.00% 0.27% 注：1、上述任何一名激励对象 ...

关于欧菲光集团股份有限公司 限制性股票第一个解除限售期解除限售条件成就及 回购注销部分限制性股票事项 的法律意见书 中国 深圳 福田区 益田路 6001 号太平金融大厦 11、12 楼 邮政编码：518038 电话(Tel.)：(0755) 8826 5288 传真(Fax.)：(0755) 8826 5537 网址（Website）：www.sundiallawfirm.com 法律意见书 广东信达律师事务所 关于欧菲光集团股份有限公司 第一个解除限售期解除限售条件成就及回购注销部分限制性股票事 项的法律意见书 信达励字（2025）第083号 致：欧菲光集团股份有限公司 广东信达律师事务所（以下简称"信达"）接受欧菲光集团股份有限公司（以 下简称"欧菲光"或"公司"）的委托，担任公司本次实行 2024 年第一期限制 性股票与股票期权激励计划（以下简称"本股权激励计划""本计划""本激励 计划"）的专项法律顾问。信达根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司股权激励管理办法》（以下简称"《管理办法》"）等有关法律、法规和规 范性文 ...

Group 1 - The company has announced a restricted stock incentive plan for 2025, granting 5 million shares at a price of 95 yuan per share to 1,368 individuals, representing 0.61% of the total share capital at the time of the announcement [2] - The incentive plan's assessment period is set from 2025 to 2027, with revenue growth targets of 20.00%, 44.00%, and 72.80% for the respective years, based on the 2024 revenue as a baseline [3] - The expected amortization expenses for the stock incentive plan from 2025 to 2028 are projected to be 57.34 million, 87.30 million, 44.76 million, and 14.80 million yuan respectively [3] Group 2 - The company has invested 2.261 billion yuan in R&D in 2024, accounting for 21.95% of its revenue, indicating a strong commitment to innovation [4] - The company has launched several strategic innovative products, including the uLinacHalosTx precision radiotherapy system and the uMR Max 3.0T MRI, which are expected to enhance its competitive position [4] - The domestic medical imaging equipment bidding market is projected to grow by 100.36% year-on-year from January to May 2025, suggesting a potential improvement in the company's performance as the market recovers [4]